Post by
swyint123888 on Nov 22, 2022 8:09am
Q3
Again the AI is weak....under 1 million 2 quarters in a row, as expected the first full 3 months of MEDI was not reported separately....we are still a heavily weighted covid test kit company...as expected....at least they made a mill, stock will do nothing is my guess....I wait....is it 2024 yet
Comment by
PendleStock on Nov 22, 2022 8:20am
AI was weak in the first three quarters. But October i think had a 3M P.O meaning it could get stronger heading to 2023. That will be the big year IMHO
Comment by
Mario79 on Nov 22, 2022 8:30am
I'm disappointed that they didn't proof read the news release as there is an error. They purchased 1,750 million shares under NCIB as of Sept 30 but they spent over 2 million dollars to purchase. Come on MG need to do better than this. This does not look good. We shareholders have been telling the company to proof read and to hire a proper PR firm. Oh well
Comment by
swyint123888 on Nov 22, 2022 8:40am
Yes Mario I have been saying for a long time Marshall should step down....like you say us shareholders deserve way way better than he is giving.....once we get out of the covid test kit company label I really hope some professionalism shows up
Comment by
PendleStock on Nov 22, 2022 9:01am
Yeah, some errors could be avoided. Next Q hope they list Medi-Call as a stand alone
Comment by
Bucks212 on Nov 22, 2022 9:28am
Speaking of Medi-call, the ramp up is slow as a snail. I hope they can still turn it around and we get great news on it next quarter
Comment by
amitchelnderson on Nov 22, 2022 3:10pm
True on the Medi-call as a stand alone. Im glad the AI did not dissapoint.
Comment by
sidharth10 on Nov 22, 2022 9:50pm
This post has been removed in accordance with Community Policy
Comment by
Bucks212 on Nov 22, 2022 9:10am
Considering their investments in AI, EVs, and Medi-call, they do seem to be controlling expenses reasonably. What is going to matter is Q1 and Q2 to see if new business segments are making any money
Comment by
Resilience19 on Nov 22, 2022 9:38am
Also picked up on the discrepancy... On the upside, it looks like the average sp for the first NCIB will have be around 0 115. The second is likely average around 0.085-0.09.
Comment by
Resilience19 on Nov 22, 2022 9:43am
Beyond this, I'm overall happy with these "post-" COVID numbers. No debt, $13M in the bank, good traction with AI revenu, increased EBITDA. Q4 was off to a good start, with the $2.4M AI contracts and Q1 2023 should include IDEAS income circa (IMO) $10M. So, compared to a lot of businesses out there, I think we, broadly, have strong metrix.
Comment by
MUTDMUTD on Nov 22, 2022 9:46am
... a very good report IMO given the current market conditions... very good indeed.... All IMO... DYODD...
Comment by
MUTDMUTD on Nov 22, 2022 10:55am
... they've now accounted for the error and reposted an NR with the over 17M shares repurchased included...
Comment by
Aiking on Nov 22, 2022 12:23pm
Good points. And if it comes to Korean students and shortages of doctors, maybe MediCall should be translated in Korean and MediCall should go for Korean doctors too. Could be useful to have Korean doctors support while studying in Canada.
Comment by
scottrose on Nov 22, 2022 12:34pm
I agree it's good to see they are not burning alot of cash as they grow the two new verticals which IMO will bring solid revs if well promoted.
Comment by
swyint123888 on Nov 22, 2022 8:44am
Yes 2023 could hit 20 million in AI if phase 2 is 10 million at the very least....20 million will help but it's clearly not enough....we need phase 2 to be off the chains and way way more than 4 or 5 million in other AI contracts, we have 380 million shares don't forget
Comment by
scottrose on Nov 22, 2022 8:32am
I do think AI will be big going forward. I am waiting to see how the nexalogy President steer the division. Hope they will give us a breakdown next quater now that EV and Medi are already in the market.
Comment by
scottrose on Nov 22, 2022 8:50am
That's a good idea, this could boost sales number and get NEXA out there.